Utrogestan

What is Utrogestan?

Utrogestan contains micronised progesterone, chemically identical to progesterone made in the body. Micronisation reduces particle size. Product name alone does not determine route, dose or indication.

In Spain, the current Utrogestan 200 mg soft vaginal capsule contains 200 mg micronised progesterone. It is a nationally authorised vaginal product.

Other progesterone brands, including Prometrium and Cyclogest, are not interchangeable names or dosing instructions for this Spanish product.

How does it work?

Progesterone acts on the endometrium and supports the luteal phase. In pregnancy it also helps maintain uterine quiescence. These actions support the specific authorised reproductive uses below, not a general period-delay or anxiety-treatment claim.

Spanish vaginal indications and dosing

Treatment requires specialist assessment and follow-up. Insert each capsule deeply into the vagina.

The first-three-month restriction for luteal support belongs to that indication; it must not erase the separate later-pregnancy prevention window. The preterm-birth decision should be shared with the patient after discussion of individual benefits, harms and practicalities. These criteria are not a platform eligibility rule or a promise of prevention.

This product is not for treating imminent preterm labour, not a contraceptive and not an authorised period-delay treatment. It has no relevant paediatric or elderly use. Do not swallow the Spanish vaginal capsules.

When it must not be used

The Spanish vaginal product is contraindicated with:

• Allergy to progesterone, soya, peanut or another ingredient.
• Jaundice or severe liver dysfunction.
• Undiagnosed vaginal bleeding.
• Breast or genital-tract cancer.
• Thrombophlebitis, thromboembolic disorders or cerebral haemorrhage.
• Porphyria.
• Missed miscarriage.
• Preterm premature rupture of membranes (PPROM).

The thrombotic conditions listed here are contraindications, not merely “discuss the risk” precautions. The product contains soya lecithin. An allergy to peanut also precludes use because of possible cross-allergy.

Monitoring, pregnancy and urgent symptoms

A complete medical examination is needed before treatment and periodically during it. Any vaginal bleeding must be investigated. Stop treatment if a missed miscarriage is diagnosed. PPROM must be excluded before preterm-birth prevention; stop if membranes rupture during treatment and contact the maternity team promptly.

Pregnancy is part of the authorised indications within their distinct windows; it is not a blanket contraindication. This product is not indicated during breastfeeding. Cholestasis of pregnancy or hepatocellular liver disease can occur with progesterone in later pregnancy: contact the clinician for jaundice, marked itching or other concerning symptoms.

Seek urgent care for chest pain, sudden breathlessness, painful leg swelling or sudden neurological symptoms. Breathing difficulty or face/throat swelling may indicate severe allergy and requires emergency care. These warnings do not replace obstetric advice or the complete leaflet.

Side effects

The Spanish vaginal label reports itching, vaginal bleeding or discharge, fatigue, burning and dizziness with unknown frequency in its post-marketing table. Local intolerance has also been described in studies; it must not be labelled universally common or used to promise fewer adverse effects than oral treatment.

Transient dizziness or fatigue can occur 1–3 hours after administration. Do not drive or use machinery while affected. Report troublesome symptoms to the treating team.

Other hormones and interactions

Norethisterone is a synthetic progestogen, not the same medicine. The products are not period-delay substitutes.

Tell the prescriber about all hormones, medicines and supplements. Enzyme inducers, including certain antiepileptics, rifampicin and St John’s wort, may increase progesterone clearance. Ketoconazole and other CYP3A4 inhibitors may increase exposure. A combination review does not mean stopping another prescribed medicine yourself.

Accessing independent advice

Prescrivia is a technology intermediary connecting patients with independent doctors. It does not prescribe, employ doctors or sell medicines. Reproductive treatment and monitoring remain the responsibility of the treating clinician. An online assessment does not establish suitability for specialist fertility or obstetric care. Any dispensing depends on a valid prescription, the actual product, applicable rules and pharmacy availability. No prescription, supply or pregnancy outcome is guaranteed.

In Spain, distance sale of prescription medicines is prohibited under Article 3.5 of Royal Legislative Decree 1/2015. An online assessment does not remove this restriction. Dispensing and access depend on the exact product and applicable national rules.

Sources

• AEMPS CIMA: Utrogestan 200 mg vaginal capsules, sections 2, 4.1–4.8 and 5.1; text revision February 2026.

This selected information does not replace the actual leaflet or individual medical advice.